Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Price Target of $18.75Defense World · Sep 28, 2026
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewsWire · Aug 31, 2026
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewsWire · Aug 11, 2026
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% – Here’s What HappenedDefense World · Aug 4, 2026
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) StockholdersGlobeNewsWire · Aug 3, 2026Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.50 | -$0.48 | Beat |
| May 12, 2026 | -$0.52 | -$0.46 | Beat |
| Mar 17, 2026 | -$0.56 | -$0.44 | Beat |
| Nov 12, 2025 | -$0.66 | -$0.64 | Beat |
| Aug 13, 2025 | -$0.51 | -$0.61 | Miss |
| May 14, 2025 | -$0.78 | -$2.52 | Miss |